당뇨병성 신증 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향, 예측(2024-2033년)

Persistence Market Research has recently published an in-depth report on the global diabetic nephropathy market, offering detailed insights into market dynamics, including drivers, trends, opportunities, and challenges. This report aims to provide a comprehensive understanding of the market structure and future outlook, catering to stakeholders involved in the healthcare and pharmaceutical sectors.

Key Insights:

• Global Market Revenue (2022): US$ 2.7 Billion
• Estimated Market Value (2033): US$ 4.9 Billion
• Global Market Growth Rate (CAGR 2022-2033): 6.8%

Global Diabetic Nephropathy Market - Report Scope:

The diabetic nephropathy market is focused on the development, production, and distribution of medications and treatments aimed at managing diabetic kidney disease (DKD), a serious complication of diabetes mellitus. The market is driven by the increasing prevalence of diabetes worldwide, which in turn is escalating the incidence of diabetic nephropathy. This market encompasses a range of products, including ACE inhibitors, ARBs, and other medications that slow the progression of kidney damage in diabetic patients.

Market Growth Drivers:

Rising Prevalence of Diabetic Patients

Diabetic nephropathy is a major complication of diabetes mellitus, and with the rising global prevalence of diabetes, the incidence of diabetic nephropathy is also increasing. Diabetic nephropathy is a leading cause of end-stage renal failure, with patients having diabetes mellitus being 10 times more likely to develop this condition compared to those without diabetes. As the number of diabetic patients continues to rise, so does the demand for effective treatments and interventions to manage diabetic nephropathy, driving the market growth.

Increasing Awareness and Early Diagnosis

With growing awareness of the risks associated with diabetes and its complications, there has been an increase in early diagnosis and management of diabetic nephropathy. Healthcare providers are focusing on regular screening of diabetic patients for kidney damage, which has led to early intervention and improved patient outcomes. This proactive approach is expected to further fuel the growth of the diabetic nephropathy market.

Market Challenges:

High Cost of Treatment

The high cost of treating diabetic nephropathy is a significant barrier to market growth. Patients with diabetic kidney disease (DKD) incur substantially higher medical costs compared to those with diabetes but without complications. According to a study published in NCBI titled "Direct medical cost of nephropathy in patients with type 2 diabetes - International Urology and Nephrology," the estimated cost for a patient with DKD was $603 (283-1267) USD, compared to $222 (141-292) USD for a diabetic patient without complications. This cost disparity can result in financial strain, particularly in low-income countries where access to affordable healthcare is limited.

Limited Treatment Options and Lack of Expertise

In low-income and less developed countries, inadequate planning and resources for diabetic nephropathy therapy, coupled with a shortage of trained specialists, present significant challenges. Moreover, there is currently no complete cure for diabetic nephropathy; existing medications only help in managing or delaying the progression of the disease. These limitations are major restraints on the global diabetic nephropathy market.

Key Questions Answered in the Report:

• What are the primary factors driving the growth of the global diabetic nephropathy market?
• Which consumer segments are leading the adoption of diabetic nephropathy treatments?
• How are advancements in medical research and treatment methods influencing the competitive landscape?
• Who are the key players in the global diabetic nephropathy market, and what strategies are they employing to maintain their market position?
• What are the emerging trends and future prospects in the global diabetic nephropathy market?

Competitive Intelligence and Business Strategy:

Leading players in the global diabetic nephropathy market, such as Abbott Laboratories, Bayer AG, and Novartis AG, are focusing on research and development, strategic collaborations, and expanding their product portfolios to maintain a competitive edge. These companies are investing in the development of novel therapies that can better manage the progression of diabetic nephropathy. Additionally, collaborations with healthcare providers and government agencies are enhancing market credibility and driving the adoption of new treatment protocols. Leveraging digital platforms to increase awareness and patient engagement is also a key strategy to strengthen market positioning.

Key Companies Profiled:

• AstraZeneca (UK.)
• Pfizer Inc (US.)
• Allergan, Inc (Ireland)
• Bristol-Myers Squibb Company (US.)
• Endo International plc (Ireland)
• Dr. Reddy's Laboratories Ltd (India)
• Sun Pharmaceutical Industries Ltd (India)
• Teva Pharmaceutical Industries Ltd (Israel)
• Novartis AG (Switzerland)
• Eli Lilly and Company (India)
• Mylan NV (US.)
• Cipla Inc (India)
• Lupin (India)
• Aurobindo Pharma (India)
• Sanofi (France)
• Fresenius SE & Co. KGaA (Germany)
• F. Hoffmann-La Roche Ltd (Switzerland)
• Takeda Pharmaceutical Company Limited (Japan)
• Abbott (US.)

Key Segments Covered in Diabetic Nephropathy Industry Research

Drug Class:

• Diuretics
• Angiotensin Receptor Blockers
• Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)
• Sodium-Glucose Transport Protein 2 (SGLT2) inhibitors
• Others

Diabetes Type:

• Type-1 Diabetes
• Type-2 Diabetes

Route of Administration:

• Oral
• Parenteral
• Others

Distribution Channel:

• Hospitals Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others

Region:

• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East and Africa

Table of Contents

1. Executive Summary

• 1.1. Global Market Outlook
• 1.2. Demand Side Trends
• 1.3. Supply Side Trends
• 1.4. Analysis and Recommendations

2. Market Overview

• 2.1. Market Coverage / Taxonomy
• 2.2. Market Definition / Scope / Limitations
• 2.3. Inclusions and Exclusions

3. Key Market Trends

• 3.1. Key Trends Impacting the Market
• 3.2. Product Innovation / Development Trends

4. Key Success Factors

• 4.1. Product Adoption Analysis
• 4.2. Disease Epidemiology
• 4.3. Regulatory Landscape
• 4.4. Pipeline Assessment
• 4.5. PESTEL Analysis
• 4.6. Porter's Analysis
• 4.7. Value Chain Analysis

5. Market Background

• 5.1. Macro-Economic Factors
  • 5.1.1. Global GDP Growth Outlook
  • 5.1.2. Global Healthcare Outlook
  • 5.1.3. Global Renal Disease Market Outlook
• 5.2. Forecast Factors - Relevance & Impact
  • 5.2.1. Development of Novel Drugs
  • 5.2.2. Regulatory Impositions
  • 5.2.3. Increasing Spending on Research and Development
  • 5.2.4. Increasing Pipeline of Therapeutic Drugs
  • 5.2.5. Rising Product Approvals
  • 5.2.6.Growing Diabetes and Obesity Populations
  • 5.2.7. Strategic Mergers and Acquisitions Among Local manufacturers
• 5.3. Market Dynamics
  • 5.3.1. Drivers
  • 5.3.2. Restraints
  • 5.3.3. Opportunity Analysis

6. COVID-19 Crisis Analysis

• 6.1. COVID-19 and Impact Analysis
  • 6.1.1. By Drug Class
  • 6.1.2. By Diabetes
  • 6.1.3. By Route of Administration
  • 6.1.4. By Distribution Channel
  • 6.1.5. By Region
• 6.2. 2024 Market Scenario

7. Global Market Demand (in Value US$ Bn) Analysis 2019-2023 and Forecast, 2024-2033

• 7.1. Historical Market Value (US$ Bn) Analysis, 2019-2023
• 7.2. Current and Future Market Value (US$ Bn) Projections, 2024-2033
  • 7.2.1. Y-o-Y Growth Trend Analysis
  • 7.2.2. Absolute $ Opportunity Analysis

8. Global Market Analysis 2019-2023 and Forecast 2024-2033, By Drug Class

• 8.1. Introduction / Key Findings
• 8.2. Historical Market Size (US$ Bn) Analysis, by Drug Class, 2019-2023
• 8.3. Current and Future Market Size (US$ Bn) Analysis and Forecast, by Drug Class, 2024-2033
  • 8.3.1. Diuretics
  • 8.3.2. Angiotensin Receptor Blockers
  • 8.3.3. Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)
  • 8.3.4. Sodium-Glucose Transport Protein 2 (SGLT2) inhibitors
  • 8.3.5. Others
• 8.4. Market Attractiveness Analysis, by Drug Class

9. Global Market Analysis 2019-2023 and Forecast 2024-2033, By Diabetes

• 9.1. Introduction / Key Findings
• 9.2. Historical Market Size (US$ Bn) Analysis, By Diabetes, 2019-2023
• 9.3. Current and Future Market Size (US$ Bn) Analysis and Forecast, by Diabetes, 2024-2033
  • 9.3.1. Type-1 Diabetes
  • 9.3.2. Type-2 Diabetes
• 9.4. Market Attractiveness Analysis, by Diabetes

10. Global Market Analysis 2019-2023 and Forecast 2024-2033, By Route of Administration

• 10.1. Introduction / Key Findings
• 10.2. Historical Market Size (US$ Bn) Analysis, By Diabetes, 2019-2023
• 10.3. Current and Future Market Size (US$ Bn) Analysis and Forecast, by Route of Administration, 2024-2033
  • 10.3.1. Oral
  • 10.3.2. Parenteral
  • 10.3.3. Others
• 10.4. Market Attractiveness Analysis, by Route of Administration

11. Global Market Analysis 2019-2023 and Forecast 2024-2033, By Distribution Channels

• 11.1. Introduction / Key Findings
• 11.2. Historical Market Size (US$ Bn) Analysis, By Diabetes, 2019-2023
• 11.3. Current and Future Market Size (US$ Bn) Analysis and Forecast, by Route of Administration, 2024-2033
  • 11.3.1. Hospital Pharmacies
  • 11.3.2. Retail Pharmacies
  • 11.3.3. Online Pharmacies
  • 11.3.4. Others
• 11.4. Market Attractiveness Analysis, by Route of Administration

12. Global Market Analysis 2019-2023 and Forecast 2024-2033, By Region

• 12.1. Introduction
• 12.2. Historical Market Size (US$ Bn) Analysis, by Region, 2019-2023
• 12.3. Current and Future Market Value (US$ Bn) Analysis and Forecast, By Region, 2024-2033
  • 12.3.1. North America
  • 12.3.2. Latin America
  • 12.3.3. Europe
  • 12.3.4. East Asia
  • 12.3.5. South Asia
  • 12.3.6. Oceania
  • 12.3.7. Middle East and Africa (MEA)
• 12.4. Market Attractiveness Analysis, by Region

13. North America Market Analysis 2019-2023 and Forecast 2024-2033

• 13.1. Introduction
• 13.2. Historical Market Size (US$ Bn) Analysis, by Market Taxonomy, 2019-2023
• 13.3. Current and Future Market Value (US$ Bn) Analysis and Forecast, by Market Taxonomy, 2024-2033
  • 13.3.1. By Country
    • 13.3.1.1. U.S.
    • 13.3.1.2. Canada
  • 13.3.2. By Drug Class
  • 13.3.3. By Diabetes
  • 13.3.4. By Route of Administration
  • 13.3.5. By Distribution Channels
• 13.4. Market Attractiveness Analysis
  • 13.4.1. By Country
  • 13.4.2. By Drug Class
  • 13.4.3. By Diabetes
  • 13.4.4. By Route of Administration
  • 13.4.5. By Distribution Channels
• 13.5. Market Trends
• 13.6. Key Market Participants - Intensity Mapping
• 13.7. Drivers and Restraints - Impact Analysis
• 13.8. Country Level Analysis & Forecast
  • 13.8.1. U.S. Market Analysis
    • 13.8.1.1. Introduction
    • 13.8.1.2. Market Analysis and Forecast, by Market Taxonomy
      • 13.8.1.2.1. By Drug Class
      • 13.8.1.2.2. By Diabetes
      • 13.8.1.2.3. By Route of Administration
      • 13.8.1.2.4. By Distribution Channels
  • 13.8.2. Canada Market Analysis
    • 13.8.2.1. Introduction
    • 13.8.2.2. Market Analysis and Forecast, by Market Taxonomy
      • 13.8.2.2.1. By Drug Class
      • 13.8.2.2.2. By Diabetes
      • 13.8.2.2.3. By Route of Administration
      • 13.8.2.2.4. By Distribution Channels

14. Latin America Market Analysis 2019-2023 and Forecast 2024-2033

• 14.1. Introduction
• 14.2. Historical Market Size (US$ Bn) Analysis, by Market Taxonomy, 2019-2023
• 14.3. Current and Future Market Value (US$ Bn) Analysis and Forecast, by Market Taxonomy, 2024-2033
  • 14.3.1. By Country
    • 14.3.1.1. Mexico
    • 14.3.1.2. Brazil
    • 14.3.1.3. Argentina
    • 14.3.1.4. Rest of Latin America
  • 14.3.2. By Drug Class
  • 14.3.3. By Diabetes
  • 14.3.4. By Route of Administration
  • 14.3.5. By Distribution Channels
• 14.4. Market Attractiveness Analysis
  • 14.4.1. By Country
  • 14.4.2. By Drug Class
  • 14.4.3. By Diabetes
  • 14.4.4. By Route of Administration
  • 14.4.5. By Distribution Channels
• 14.5. Market Trends
• 14.6. Key Market Participants - Intensity Mapping
• 14.7. Drivers and Restraints - Impact Analysis
• 14.8. Country Level Analysis & Forecast
  • 14.8.1. Mexico Market Analysis
    • 14.8.1.1. Introduction
    • 14.8.1.2. Market Analysis and Forecast, by Market Taxonomy
      • 14.8.1.2.1. By Drug Class
      • 14.8.1.2.2. By Diabetes
      • 14.8.1.2.3. By Route of Administration
      • 14.8.1.2.4. By Distribution Channels
  • 14.8.2. Brazil Market Analysis
    • 14.8.2.1. Introduction
    • 14.8.2.2. Market Analysis and Forecast, by Market Taxonomy
      • 14.8.2.2.1. By Drug Class
      • 14.8.2.2.2. By Diabetes
      • 14.8.2.2.3. By Route of Administration
      • 14.8.2.2.4. By Distribution Channels
  • 14.8.3. Argentina Market Analysis
    • 14.8.3.1. Introduction
    • 14.8.3.2. Market Analysis and Forecast, by Market Taxonomy
      • 14.8.3.2.1. By Drug Class
      • 14.8.3.2.2. By Diabetes
      • 14.8.3.2.3. By Route of Administration
      • 14.8.3.2.4. By Distribution Channels

15. Europe Market Analysis 2019-2023 and Forecast 2024-2033

• 15.1. Introduction
• 15.2. Historical Market Size (US$ Bn) Analysis, by Market Taxonomy, 2019-2023
• 15.3. Current and Future Market Value (US$ Bn) Analysis and Forecast, by Market Taxonomy, 2024-2033
  • 15.3.1. By Country
    • 15.3.1.1. Germany
    • 15.3.1.2. Italy
    • 15.3.1.3. France
    • 15.3.1.4. U.K.
    • 15.3.1.5. Spain
    • 15.3.1.6. BENELUX
    • 15.3.1.7. Russia
    • 15.3.1.8. Nordic Countries
    • 15.3.1.9. Rest of Europe
  • 15.3.2. By Drug Class
  • 15.3.3. By Diabetes
  • 15.3.4. By Route of Administration
  • 15.3.5. By Distribution Channels
• 15.4. Market Attractiveness Analysis
  • 15.4.1. By Country
  • 15.4.2. By Drug Class
  • 15.4.3. By Diabetes
  • 15.4.4. By Route of Administration
  • 15.4.5. By Distribution Channels
• 15.5. Market Trends
• 15.6. Key Market Participants - Intensity Mapping
• 15.7. Drivers and Restraints - Impact Analysis
• 15.8. Country Level Analysis & Forecast
  • 15.8.1. Germany Market Analysis
    • 15.8.1.1. Introduction
    • 15.8.1.2. Market Analysis and Forecast, by Market Taxonomy
      • 15.8.1.2.1. By Drug Class
      • 15.8.1.2.2. By Diabetes
      • 15.8.1.2.3. By Route of Administration
      • 15.8.1.2.4. By Distribution Channels
  • 15.8.2. Italy Market Analysis
    • 15.8.2.1. Introduction
    • 15.8.2.2. Market Analysis and Forecast, by Market Taxonomy
      • 15.8.2.2.1. By Drug Class
      • 15.8.2.2.2. By Diabetes
      • 15.8.2.2.3. By Route of Administration
      • 15.8.2.2.4. By Distribution Channels
  • 15.8.3. France Market Analysis
    • 15.8.3.1. Introduction
    • 15.8.3.2. Market Analysis and Forecast, by Market Taxonomy
      • 15.8.3.2.1. By Drug Class
      • 15.8.3.2.2. By Diabetes
      • 15.8.3.2.3. By Route of Administration
      • 15.8.3.2.4. By Distribution Channels
  • 15.8.4. U.K. Market Analysis
    • 15.8.4.1. Introduction
    • 15.8.4.2. Market Analysis and Forecast, by Market Taxonomy
      • 15.8.4.2.1. By Drug Class
      • 15.8.4.2.2. By Diabetes
      • 15.8.4.2.3. By Route of Administration
      • 15.8.4.2.4. By Distribution Channels
  • 15.8.5. Spain Market Analysis
    • 15.8.5.1. Introduction
    • 15.8.5.2. Market Analysis and Forecast, by Market Taxonomy
      • 15.8.5.2.1. By Drug Class
      • 15.8.5.2.2. By Diabetes
      • 15.8.5.2.3. By Route of Administration
      • 15.8.5.2.4. By Distribution Channels
  • 15.8.6. BENELUX Market Analysis
    • 15.8.6.1. Introduction
    • 15.8.6.2. Market Analysis and Forecast, by Market Taxonomy
      • 15.8.6.2.1. By Drug Class
      • 15.8.6.2.2. By Diabetes
      • 15.8.6.2.3. By Route of Administration
      • 15.8.6.2.4. By Distribution Channels
  • 15.8.7. Russia Market Analysis
    • 15.8.7.1. Introduction
    • 15.8.7.2. Market Analysis and Forecast, by Market Taxonomy
      • 15.8.7.2.1. By Drug Class
      • 15.8.7.2.2. By Diabetes
      • 15.8.7.2.3. By Route of Administration
      • 15.8.7.2.4. By Distribution Channels
  • 15.8.8. Nordic Countries Market Analysis
    • 15.8.8.1. Introduction
    • 15.8.8.2. Market Analysis and Forecast, by Market Taxonomy
      • 15.8.8.2.1. By Drug Class
      • 15.8.8.2.2. By Diabetes
      • 15.8.8.2.3. By Route of Administration
      • 15.8.8.2.4. By Distribution Channels

16. East Asia Market Analysis 2019-2023 and Forecast 2024-2033

• 16.1. Introduction
• 16.2. Historical Market End User (US$ Bn) Analysis, by Market Taxonomy, 2019-2023
• 16.3. Current and Future Market Value (US$ Bn) Analysis and Forecast, by Market Taxonomy, 2024-2033
  • 16.3.1. By Country
    • 16.3.1.1. China
    • 16.3.1.2. Japan
    • 16.3.1.3. South Korea
  • 16.3.2. By Drug Class
  • 16.3.3. By Diabetes
  • 16.3.4. By Route of Administration
  • 16.3.5. By Distribution Channels
• 16.4. Market Attractiveness Analysis
  • 16.4.1. By Drug Class
  • 16.4.2. By Diabetes
  • 16.4.3. By Route of Administration
  • 16.4.4. By Distribution Channels
• 16.5. Market Trends
• 16.6. Key Market Participants - Intensity Mapping
• 16.7. Drivers and Restraints - Impact Analysis
• 16.8. Country Level Analysis & Forecast
  • 16.8.1. China Market Analysis
    • 16.8.1.1. Introduction
    • 16.8.1.2. Market Analysis and Forecast, by Market Taxonomy
      • 16.8.1.2.1. By Drug Class
      • 16.8.1.2.2. By Diabetes
      • 16.8.1.2.3. By Route of Administration
      • 16.8.1.2.4. By Distribution Channels
  • 16.8.2. Japan Market Analysis
    • 16.8.2.1. Introduction
    • 16.8.2.2. Market Analysis and Forecast, by Market Taxonomy
      • 16.8.2.2.1. By Drug Class
      • 16.8.2.2.2. By Diabetes
      • 16.8.2.2.3. By Route of Administration
      • 16.8.2.2.4. By Distribution Channels
  • 16.8.3. South Korea Market Analysis
    • 16.8.3.1. Introduction
    • 16.8.3.2. Market Analysis and Forecast, by Market Taxonomy
      • 16.8.3.2.1. By Drug Class
      • 16.8.3.2.2. By Diabetes
      • 16.8.3.2.3. By Route of Administration
      • 16.8.3.2.4. By Distribution Channels

17. South Asia Market Analysis 2019-2023 and Forecast 2024-2033

• 17.1. Introduction
• 17.2. Historical Market Size (US$ Bn) Analysis, by Market Taxonomy, 2019-2023
• 17.3. Current and Future Market Value (US$ Bn) Analysis and Forecast, by Market Taxonomy, 2024-2033
  • 17.3.1. By Country
    • 17.3.1.1. India
    • 17.3.1.2. Indonesia
    • 17.3.1.3. Malaysia
    • 17.3.1.4. Thailand
    • 17.3.1.5. Rest of South Asia
  • 17.3.2. By Drug Class
  • 17.3.3. By Diabetes
  • 17.3.4. By Route of Administration
  • 17.3.5. By Distribution Channels
• 17.4. Market Attractiveness Analysis
  • 17.4.1. By Country
  • 17.4.2. By Drug Class
  • 17.4.3. By Diabetes
  • 17.4.4. By Route of Administration
  • 17.4.5. By Distribution Channels
• 17.5. Market Trends
• 17.6. Key Market Participants - Intensity Mapping
• 17.7. Drivers and Restraints - Impact Analysis
• 17.8. Country Level Analysis & Forecast
  • 17.8.1. India Market Analysis
    • 17.8.1.1. Introduction
    • 17.8.1.2. Market Analysis and Forecast, by Market Taxonomy
      • 17.8.1.2.1. By Drug Class
      • 17.8.1.2.2. By Diabetes
      • 17.8.1.2.3. By Route of Administration
      • 17.8.1.2.4. By Distribution Channels
  • 17.8.2. Indonesia Market Analysis
    • 17.8.2.1. Introduction
    • 17.8.2.2. Market Analysis and Forecast, by Market Taxonomy
      • 17.8.2.2.1. By Drug Class
      • 17.8.2.2.2. By Diabetes
      • 17.8.2.2.3. By Route of Administration
      • 17.8.2.2.4. By Distribution Channels
  • 17.8.3. Malaysia Market Analysis
    • 17.8.3.1. Introduction
    • 17.8.3.2. Market Analysis and Forecast, by Market Taxonomy
      • 17.8.3.2.1. By Drug Class
      • 17.8.3.2.2. By Diabetes
      • 17.8.3.2.3. By Route of Administration
      • 17.8.3.2.4. By Distribution Channels
  • 17.8.4. Thailand Market Analysis
    • 17.8.4.1. Introduction
    • 17.8.4.2. Market Analysis and Forecast, by Market Taxonomy
      • 17.8.4.2.1. By Drug Class
      • 17.8.4.2.2. By Diabetes
      • 17.8.4.2.3. By Route of Administration
      • 17.8.4.2.4. By Distribution Channels

18. Oceania Market 2019-2023 and Forecast 2024-2033

• 18.1. Introduction
• 18.2. Historical Market Size (US$ Bn) Analysis, by Market Taxonomy, 2019-2023
• 18.3. Current and Future Market Value (US$ Bn) Analysis and Forecast, by Market Taxonomy, 2024-2033
  • 18.3.1. By Country
    • 18.3.1.1. Australia
    • 18.3.1.2. New Zealand
  • 18.3.2. By Drug Class
  • 18.3.3. By Diabetes
  • 18.3.4. By Route of Administration
  • 18.3.5. By Distribution Channels
• 18.4. Market Attractiveness Analysis
  • 18.4.1. By Country
  • 18.4.2. By Drug Class
  • 18.4.3. By Diabetes
  • 18.4.4. By Route of Administration
  • 18.4.5. By Distribution Channels
• 18.5. Key Market Participants - Intensity Mapping
• 18.6. Key Market Participants - Intensity Mapping
• 18.7. Drivers and Restraints - Impact Analysis
• 18.8. Country Level Analysis & Forecast
  • 18.8.1. Australia Market Analysis
    • 18.8.1.1. Introduction
    • 18.8.1.2. Market Analysis and Forecast, by Market Taxonomy
      • 18.8.1.2.1. By Drug Class
      • 18.8.1.2.2. By Diabetes
      • 18.8.1.2.3. By Route of Administration
      • 18.8.1.2.4. By Distribution Channels
  • 18.8.2. New Zealand Market Analysis
    • 18.8.2.1. Introduction
    • 18.8.2.2. Market Analysis and Forecast, by Market Taxonomy
      • 18.8.2.2.1. By Drug Class
      • 18.8.2.2.2. By Diabetes
      • 18.8.2.2.3. By Route of Administration
      • 18.8.2.2.4. By Distribution Channels

19. Middle East and Africa (MEA) Market Analysis 2019-2023 and Forecast 2024-2033

• 19.1. Introduction
• 19.2. Historical Market Size (US$ Bn) Analysis, by Market Taxonomy, 2019-2023
• 19.3. Current and Future Market Value (US$ Bn) Analysis and Forecast, by Market Taxonomy, 2024-2033
  • 19.3.1. By Country
    • 19.3.1.1. GCC Countries
    • 19.3.1.2. Turkiye
    • 19.3.1.3. South Africa
    • 19.3.1.4. North Africa
    • 19.3.1.5. Rest of Middle East and Africa
  • 19.3.2. By Drug Class
  • 19.3.3. By Diabetes
  • 19.3.4. By Route of Administration
  • 19.3.5. By Distribution Channels
• 19.4. Market Attractiveness Analysis
  • 19.4.1. By Drug Class
  • 19.4.2. By Diabetes
  • 19.4.3. By Route of Administration
  • 19.4.4. By Distribution Channels
• 19.5. Market Trends
• 19.6. Key Market Participants - Intensity Mapping
• 19.7. Drivers and Restraints - Impact Analysis
• 19.8. Country Level Analysis & Forecast
  • 19.8.1. GCC Countries Market Analysis
    • 19.8.1.1. Introduction
    • 19.8.1.2. Market Analysis and Forecast, by Market Taxonomy
      • 19.8.1.2.1. By Drug Class
      • 19.8.1.2.2. By Diabetes
      • 19.8.1.2.3. By Route of Administration
      • 19.8.1.2.4. By Distribution Channels
  • 19.8.2. Turkiye Market Analysis
    • 19.8.2.1. Introduction
    • 19.8.2.2. Market Analysis and Forecast, by Market Taxonomy
      • 19.8.2.2.1. By Drug Class
      • 19.8.2.2.2. By Diabetes
      • 19.8.2.2.3. By Route of Administration
      • 19.8.2.2.4. By Distribution Channels
  • 19.8.3. South Africa Market Analysis
    • 19.8.3.1. Introduction
    • 19.8.3.2. Market Analysis and Forecast, by Market Taxonomy
      • 19.8.3.2.1. By Drug Class
      • 19.8.3.2.2. By Diabetes
      • 19.8.3.2.3. By Route of Administration
      • 19.8.3.2.4. By Distribution Channels
  • 19.8.4. North Africa Market Analysis
    • 19.8.4.1. Introduction
    • 19.8.4.2. Market Analysis and Forecast, by Market Taxonomy
      • 19.8.4.2.1. By Drug Class
      • 19.8.4.2.2. By Diabetes
      • 19.8.4.2.3. By Route of Administration
      • 19.8.4.2.4. By Distribution Channels

20. Market Structure Analysis

• 20.1. Market Analysis, by Tier of Companies
• 20.2. Market Share Analysis of Top Players
• 20.3. Market Presence Analysis

21. Competition Analysis

• 21.1. Competition Dashboard
• 21.2. Competition Benchmarking
• 21.3. Competition Deep Dive
  • 21.3.1. AstraZeneca (UK.)
    • 21.3.1.1. Overview
    • 21.3.1.2. Product Portfolio
    • 21.3.1.3. Sales Footprint
    • 21.3.1.4. Key Financials
    • 21.3.1.5. SWOT Analysis
    • 21.3.1.6. Strategy Overview
      • 21.3.1.6.1. Marketing Strategy
      • 21.3.1.6.2. Product Strategy
      • 21.3.1.6.3. Channel Strategy
  • 21.3.2. Pfizer Inc (US.)
    • 21.3.2.1. Overview
    • 21.3.2.2. Product Portfolio
    • 21.3.2.3. Sales Footprint
    • 21.3.2.4. Key Financials
    • 21.3.2.5. SWOT Analysis
    • 21.3.2.6. Strategy Overview
      • 21.3.2.6.1. Marketing Strategy
      • 21.3.2.6.2. Product Strategy
      • 21.3.2.6.3. Channel Strategy
  • 21.3.3. Allergan, Inc (Ireland)
    • 21.3.3.1. Overview
    • 21.3.3.2. Product Portfolio
    • 21.3.3.3. Sales Footprint
    • 21.3.3.4. Key Financials
    • 21.3.3.5. SWOT Analysis
    • 21.3.3.6. Strategy Overview
      • 21.3.3.6.1. Marketing Strategy
      • 21.3.3.6.2. Product Strategy
      • 21.3.3.6.3. Channel Strategy
  • 21.3.4. Bristol-Myers Squibb Company (US.)
    • 21.3.4.1. Overview
    • 21.3.4.2. Product Portfolio
    • 21.3.4.3. Sales Footprint
    • 21.3.4.4. Key Financials
    • 21.3.4.5. SWOT Analysis
    • 21.3.4.6. Strategy Overview
      • 21.3.4.6.1. Marketing Strategy
      • 21.3.4.6.2. Product Strategy
      • 21.3.4.6.3. Channel Strategy
  • 21.3.5. Endo International plc (Ireland)
    • 21.3.5.1. Overview
    • 21.3.5.2. Product Portfolio
    • 21.3.5.3. Sales Footprint
    • 21.3.5.4. Key Financials
    • 21.3.5.5. SWOT Analysis
    • 21.3.5.6. Strategy Overview
      • 21.3.5.6.1. Marketing Strategy
      • 21.3.5.6.2. Product Strategy
      • 21.3.5.6.3. Channel Strategy
  • 21.3.6. Dr. Reddy's Laboratories Ltd (India)
    • 21.3.6.1. Overview
    • 21.3.6.2. Product Portfolio
    • 21.3.6.3. Sales Footprint
    • 21.3.6.4. Key Financials
    • 21.3.6.5. SWOT Analysis
    • 21.3.6.6. Strategy Overview
      • 21.3.6.6.1. Marketing Strategy
      • 21.3.6.6.2. Product Strategy
      • 21.3.6.6.3. Channel Strategy
  • 21.3.7. Sun Pharmaceutical Industries Ltd (India)
    • 21.3.7.1. Overview
    • 21.3.7.2. Product Portfolio
    • 21.3.7.3. Sales Footprint
    • 21.3.7.4. Key Financials
    • 21.3.7.5. SWOT Analysis
    • 21.3.7.6. Strategy Overview
      • 21.3.7.6.1. Marketing Strategy
      • 21.3.7.6.2. Product Strategy
      • 21.3.7.6.3. Channel Strategy
  • 21.3.8. Teva Pharmaceutical Industries Ltd (Israel)
    • 21.3.8.1. Overview
    • 21.3.8.2. Product Portfolio
    • 21.3.8.3. Sales Footprint
    • 21.3.8.4. Key Financials
    • 21.3.8.5. SWOT Analysis
    • 21.3.8.6. Strategy Overview
      • 21.3.8.6.1. Marketing Strategy
      • 21.3.8.6.2. Product Strategy
      • 21.3.8.6.3. Channel Strategy
  • 21.3.9. Novartis AG (Switzerland)
    • 21.3.9.1. Overview
    • 21.3.9.2. Product Portfolio
    • 21.3.9.3. Sales Footprint
    • 21.3.9.4. Key Financials
    • 21.3.9.5. SWOT Analysis
    • 21.3.9.6. Strategy Overview
      • 21.3.9.6.1. Marketing Strategy
      • 21.3.9.6.2. Product Strategy
      • 21.3.9.6.3. Channel Strategy
  • 21.3.10. Eli Lilly and Company (India)
    • 21.3.10.1. Overview
    • 21.3.10.2. Product Portfolio
    • 21.3.10.3. Sales Footprint
    • 21.3.10.4. Key Financials
    • 21.3.10.5. SWOT Analysis
    • 21.3.10.6. Strategy Overview
      • 21.3.10.6.1. Marketing Strategy
      • 21.3.10.6.2. Product Strategy
      • 21.3.10.6.3. Channel Strategy
  • 21.3.11. Mylan NV (US.)
    • 21.3.11.1. Overview
    • 21.3.11.2. Product Portfolio
    • 21.3.11.3. Sales Footprint
    • 21.3.11.4. Key Financials
    • 21.3.11.5. SWOT Analysis
    • 21.3.11.6. Strategy Overview
      • 21.3.11.6.1. Marketing Strategy
      • 21.3.11.6.2. Product Strategy
      • 21.3.11.6.3. Channel Strategy
  • 21.3.12. Cipla Inc (India)
    • 21.3.12.1. Overview
    • 21.3.12.2. Product Portfolio
    • 21.3.12.3. Sales Footprint
    • 21.3.12.4. Key Financials
    • 21.3.12.5. SWOT Analysis
    • 21.3.12.6. Strategy Overview
      • 21.3.12.6.1. Marketing Strategy
      • 21.3.12.6.2. Product Strategy
      • 21.3.12.6.3. Channel Strategy
  • 21.3.13. Lupin (India)
    • 21.3.13.1. Overview
    • 21.3.13.2. Product Portfolio
    • 21.3.13.3. Sales Footprint
    • 21.3.13.4. Key Financials
    • 21.3.13.5. SWOT Analysis
    • 21.3.13.6. Strategy Overview
      • 21.3.13.6.1. Marketing Strategy
      • 21.3.13.6.2. Product Strategy
      • 21.3.13.6.3. Channel Strategy
  • 21.3.14. Aurobindo Pharma (India)
    • 21.3.14.1. Overview
    • 21.3.14.2. Product Portfolio
    • 21.3.14.3. Sales Footprint
    • 21.3.14.4. Key Financials
    • 21.3.14.5. SWOT Analysis
    • 21.3.14.6. Strategy Overview
      • 21.3.14.6.1. Marketing Strategy
      • 21.3.14.6.2. Product Strategy
      • 21.3.14.6.3. Channel Strategy
  • 21.3.15. Sanofi (France)
    • 21.3.15.1. Overview
    • 21.3.15.2. Product Portfolio
    • 21.3.15.3. Sales Footprint
    • 21.3.15.4. Key Financials
    • 21.3.15.5. SWOT Analysis
    • 21.3.15.6. Strategy Overview
      • 21.3.15.6.1. Marketing Strategy
      • 21.3.15.6.2. Product Strategy
      • 21.3.15.6.3. Channel Strategy
  • 21.3.16. Fresenius SE & Co. KGaA (Germany)
    • 21.3.16.1. Overview
    • 21.3.16.2. Product Portfolio
    • 21.3.16.3. Sales Footprint
    • 21.3.16.4. Key Financials
    • 21.3.16.5. SWOT Analysis
    • 21.3.16.6. Strategy Overview
      • 21.3.16.6.1. Marketing Strategy
      • 21.3.16.6.2. Product Strategy
      • 21.3.16.6.3. Channel Strategy
  • 21.3.17. F. Hoffmann-La Roche Ltd (Switzerland)
    • 21.3.17.1. Overview
    • 21.3.17.2. Product Portfolio
    • 21.3.17.3. Sales Footprint
    • 21.3.17.4. Key Financials
    • 21.3.17.5. SWOT Analysis
    • 21.3.17.6. Strategy Overview
      • 21.3.17.6.1. Marketing Strategy
      • 21.3.17.6.2. Product Strategy
      • 21.3.17.6.3. Channel Strategy
  • 21.3.18. Takeda Pharmaceutical Company Limited (Japan)
    • 21.3.18.1. Overview
    • 21.3.18.2. Product Portfolio
    • 21.3.18.3. Sales Footprint
    • 21.3.18.4. Key Financials
    • 21.3.18.5. SWOT Analysis
    • 21.3.18.6. Strategy Overview
      • 21.3.18.6.1. Marketing Strategy
      • 21.3.18.6.2. Product Strategy
      • 21.3.18.6.3. Channel Strategy
  • 21.3.19. Abbott (US.)
    • 21.3.19.1. Overview
    • 21.3.19.2. Product Portfolio
    • 21.3.19.3. Sales Footprint
    • 21.3.19.4. Key Financials
    • 21.3.19.5. SWOT Analysis
    • 21.3.19.6. Strategy Overview
      • 21.3.19.6.1. Marketing Strategy
      • 21.3.19.6.2. Product Strategy
      • 21.3.19.6.3. Channel Strategy

22. Assumptions and Acronyms Used

23. Research Methodology